Table 2.
Survival time and frequency of treatment according to baseline characteristics in patients with RPRTs (n = 1357)
| Baseline characteristics | Median survival, months (95% CI) | Median frequency of treatment (range) | p value* |
|---|---|---|---|
| Age (years) | <0.01 | ||
| <40 | 12.3 (6.7–17.8) | 3.0 (1–16) | |
| 40–60 | 20.6 (18.1–23.1) | 3.0 (1–18) | |
| ≥60 | 26.9 (24.7–29.1) | 4.0 (1–20) | |
| Sex | 0.52 | ||
| Male | 22.0 (20.0–23.9) | 3.0 (1–20) | |
| Female | 29.9 (23.5–36.2) | 3.0 (1–16) | |
| Etiology | 0.41 | ||
| Viral | 22.5 (20.5–24.6) | 3.0 (1–20) | |
| Non-viral | 27.7 (23.9–31.4) | 4.0 (1–17) | |
| Child–Pugh classa | 0.09 | ||
| A | 24.0 (21.8–26.2) | 3.0 (1–20) | |
| B | 18.9 (15.3–22.4) | 3.0 (1–16) | |
| C | 6.2 (4.1–8.2) | 2.0(1–7) | |
| BCLC | <0.01 | ||
| 0 | 92.1 (43.3–141.0) | 3.0 (1–12) | |
| A | 52.5 (48.1–56.9) | 4.0 (1–15) | |
| B | 32.1 (27.6–36.5) | 5 (1–20) | |
| C | 14.8 (13.1–16.5) | 3 (1–20) | |
| mUICC | <0.01 | ||
| I | 67.1 (43.3–91.0) | 3.0 (1–17) | |
| II | 42.4 (37.4–47.4) | 4.0 (1–16) | |
| III | 24.4 (21.8–27.0) | 4.0 (1–20) | |
| IV | 8.7 (7.8–9.6) | 3.0 (1–20) | |
| Tumor type | <0.01 | ||
| Well-defined | 33.9 (30.5–37.3) | 4.0 (1–20) | |
| Ill-defined | 8.4 (7.5–9.3) | 2.0 (1–14) | |
| Initial modality | <0.01 | ||
| Resection | 52.5 (41.8–63.2) | 4 (1–16) | |
| RFA/PEI | 50.2 (30.8–69.6) | 3 (1–14) | |
| TACE | 22.5 (20.3–24.7) | 4 (1–20) | |
| EBRT | 10.0 (7.4–12.6) | 2 (1–14) | |
| Systemic chemotherapy | 5.8 (4.6–7.0) | 1 (1–11) |
CI confidential interval, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, mUICC modified Union of International Cancer Control, RFA radiation frequency ablation, PEI percutaneous ethanol injection, TACE transarterial chemoembolization, EBRT external beam radiation therapy
* p value for treatment frequency
a Child C was excluded from statistical tests because the number of patients was four